Cargando…

Synergistic Neuroprotection by a PAF Antagonist Plus a Docosanoid in Experimental Ischemic Stroke: Dose-Response and Therapeutic Window

OBJECTIVE: We tested the hypothesis that blocking pro-inflammatory platelet-activating factor receptor (PAFR) with LAU-0901 (LAU) plus administering a selected docosanoid, aspirin-triggered neuroprotectin D1 (AT-NPD1), which activates cell-survival pathways after middle cerebral artery occlusion (MC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reid, Madigan M., Obenaus, Andre, Mukherjee, Pranab K., Khoutorova, Larissa, Roque, Cassia R., Petasis, Nicos A., Oria, Reinaldo B., Belayev, Ludmila, Bazan, Nicolas G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9976619/ https://www.ncbi.nlm.nih.gov/pubmed/35717719 http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2022.106585

Ejemplares similares

Combined Therapy With Avastin, a PAF Receptor Antagonist and a Lipid Mediator Inhibited Glioblastoma Tumor Growth
por: Cruz Flores, Valerie A., et al.
Publicado: (2021)

Blocking pro-inflammatory platelet-activating factor receptors and activating cell survival pathways: A novel therapeutic strategy in experimental ischemic stroke
por: Belayev, Ludmila, et al.
Publicado: (2020)

Integrated inflammatory signaling landscape response after delivering Elovanoid free-fatty-acid precursors leading to experimental stroke neuroprotection
por: Reid, Madigan M., et al.
Publicado: (2023)

NPD1 Plus RvD1 Mediated Ischemic Stroke Penumbra Protection Increases Expression of Pro-homeostatic Microglial and Astrocyte Genes
por: Reid, Madigan M., et al.
Publicado: (2023)

Docosahexaenoic acid complexed to human albumin in experimental stroke: neuroprotective efficacy with a wide therapeutic window
por: Eady, Tiffany N, et al.
Publicado: (2012)

Superior Neuroprotective Efficacy of LAU-0901, a Novel Platelet-Activating Factor Antagonist, in Experimental Stroke
por: Belayev, Ludmila, et al.
Publicado: (2011)

DHA modulates MANF and TREM2 abundance, enhances neurogenesis, reduces infarct size, and improves neurological function after experimental ischemic stroke
por: Belayev, Ludmila, et al.
Publicado: (2020)

Neuroprotectin D1 upregulates Iduna expression and provides protection in cellular uncompensated oxidative stress and in experimental ischemic stroke
por: Belayev, Ludmila, et al.
Publicado: (2017)

Elovanoids are a novel class of homeostatic lipid mediators that protect neural cell integrity upon injury
por: Bhattacharjee, Surjyadipta, et al.
Publicado: (2017)

Molecular mechanisms of signaling via the docosanoid neuroprotectin D1 for cellular homeostasis and neuroprotection
por: Asatryan, Aram, et al.
Publicado: (2017)

Docosahexaenoic Acid Therapy of Experimental Ischemic Stroke
por: Belayev, Ludmila, et al.
Publicado: (2010)

Docosahexaenoic acid improves behavior and attenuates blood–brain barrier injury induced by focal cerebral ischemia in rats
por: Hong, Sung-Ha, et al.
Publicado: (2015)

Acute Treatment with Docosahexaenoic Acid Complexed to Albumin Reduces Injury after a Permanent Focal Cerebral Ischemia in Rats
por: Eady, Tiffany N., et al.
Publicado: (2013)

Retinal Pigment Epithelium and Photoreceptor Preconditioning Protection Requires Docosanoid Signaling
por: Knott, Eric J., et al.
Publicado: (2017)

cRel and Wnt5a/Frizzled 5 Receptor-Mediated Inflammatory Regulation Reveal Novel Neuroprotectin D1 Targets for Neuroprotection
por: Calandria, Jorgelina M., et al.
Publicado: (2022)

Docosahexaenoic Acid Signaling Modulates Cell Survival in Experimental Ischemic Stroke Penumbra and Initiates Long-Term Repair in Young and Aged Rats
por: Eady, Tiffany N., et al.
Publicado: (2012)

Correction to: cRel and Wnt5a/Frizzled 5 Receptor-Mediated Inflammatory Regulation Reveal Novel Neuroprotectin D1 Targets for Neuroprotection
por: Calandria, Jorgelina M., et al.
Publicado: (2022)

Elovanoids are novel cell-specific lipid mediators necessary for neuroprotective signaling for photoreceptor cell integrity
por: Jun, Bokkyoo, et al.
Publicado: (2017)

Docosanoid signaling modulates corneal nerve regeneration: effect on tear secretion, wound healing, and neuropathic pain
por: Pham, Thang L., et al.
Publicado: (2021)

The Docosanoid Neuroprotectin D1 Induces TH-Positive Neuronal Survival in a Cellular Model of Parkinson’s Disease
por: Calandria, Jorgelina M., et al.
Publicado: (2015)

High levels of eicosanoids and docosanoids in the lungs of intubated COVID‐19 patients
por: Archambault, Anne‐Sophie, et al.
Publicado: (2021)

Ataxin-1 Poly(Q)-induced Proteotoxic Stress and Apoptosis Are Attenuated in Neural Cells by Docosahexaenoic Acid-derived Neuroprotectin D1
por: Calandria, Jorgelina M., et al.
Publicado: (2012)

PAF‐induced inflammatory and immuno‐allergic ophthalmic diseases and their mitigation with PAF receptor antagonists: Cell and nuclear effects
por: Sharif, Najam A.
Publicado: (2022)

Human and Mouse Eosinophils Differ in Their Ability to Biosynthesize Eicosanoids, Docosanoids, the Endocannabinoid 2-Arachidonoyl-glycerol and Its Congeners
por: Archambault, Anne-Sophie, et al.
Publicado: (2022)

Rupatadine: efficacy and safety of a non-sedating antihistamine with PAF-antagonist effects
por: Shamizadeh, Soja, et al.
Publicado: (2014)

Multiprong control of glioblastoma multiforme invasiveness: blockade of pro-inflammatory signaling, anti-angiogenesis, and homeostasis restoration
por: Bazan, Nicolas G., et al.
Publicado: (2021)

Hippocampal Neuro-Networks and Dendritic Spine Perturbations in Epileptogenesis Are Attenuated by Neuroprotectin D1
por: Musto, Alberto E., et al.
Publicado: (2015)

Degradation Characteristics of a Novel PAF Receptor Antagonist, SY0916, in Aqueous Solution
por: Jin, Bo, et al.
Publicado: (2019)

Elovanoids downregulate SARS-CoV-2 cell-entry, canonical mediators and enhance protective signaling in human alveolar cells
por: Calandria, Jorgelina M., et al.
Publicado: (2021)

Functional Consequences of Mutations and Polymorphisms in the Coding Region of the PAF Acetylhydrolase (PAF-AH) Gene
por: Stafforini, Diana M.
Publicado: (2009)

Pulmonary injury after intestinal ischemia and reperfusion injury: effects of treatment with lexipafant, a PAF antagonist
por: Börjesson, A, et al.
Publicado: (1998)

Leyes PAF fiscal, 2008.
Publicado: (2008)

PAF and Haematopoiesis. I. 5-Fluoro-Uracil Induces PAF Production in Haematopoietic Organs of Rats
por: Denizot, Y., et al.
Publicado: (1994)

Antiplatelet Aggregation and Platelet Activating Factor (PAF) Receptor Antagonistic Activities of the Essential Oils of Five Goniothalamus Species
por: Moharam, Bushra Abdulkarim, et al.
Publicado: (2010)

Paf1 and Ctr9 subcomplex formation is essential for Paf1 complex assembly and functional regulation
por: Xie, Ying, et al.
Publicado: (2018)

PAF49: An RNA Polymerase I subunit essential for rDNA transcription and stabilization of PAF53
por: McNamar, Rachel, et al.
Publicado: (2023)

Elucidating the structure and functions of Resolvin D6 isomers on nerve regeneration with a distinctive trigeminal transcriptome
por: Pham, Thang L., et al.
Publicado: (2021)

Fish polar lipids retard atherosclerosis in rabbits by down-regulating PAF biosynthesis and up-regulating PAF catabolism
por: Nasopoulou, Constantina, et al.
Publicado: (2011)

Increased susceptibility to bladder inflammation in smokers: targeting the PAF–PAF receptor interaction to manage inflammatory cell recruitment
por: Marentette, John, et al.
Publicado: (2015)

Platelet-Activating Factor (PAF) Antagonistic Activity of a New Biflavonoid from Garcinia nervosa var. pubescens King
por: Jalil, Juriyati, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_4qpkt2nsrrs3gd74n7j9a5flif